PeterKabosPeter Kabos39.74389450000000-104.839435200000002455Kabos, Peter303/724-4690Professorprns:coAuthorOfcoauthor ofprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:grantAwardedBygrant awarded byprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:principalInvestigatorNameprincipal investigator nameprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:startDatestart dateprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:address2address line 2vivo:address3address line 3vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provinceAgreementvivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionGrantvivo:hasResearchArearesearch areasvivo:hasResearcherRoleresearch activitiesvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsvivo:phoneNumberphonePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleResearcher Rolevivo:researcherRoleOfresearcher role ofRolevivo:roleContributesTocontributes tovivo:sponsorAwardIdsponsor award idrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonAuthorship 810164Authorship 83424Authorship 88261Authorship 924371Authorship 926242Authorship 124304725758253Tentler JJ, Ionkina AA, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JRMolecular cancer therapeuticsTentler JJ, Ionkina AA, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JR. p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. Mol Cancer Ther. 2015 May; 14(5):1117-29.Mol Cancer Ther2015-03-10T00:00:002015p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer.Authorship 127037525241899Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CAOncogeneFinlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 2015 Jul; 34(28):3676-87.Oncogene2014-09-22T00:00:002014Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a.Authorship 131475726384804Jasem J, Altoos B, Fisher CM, Elias AD, Kounalakis N, Borges VF, Kabos POncology (Williston Park, N.Y.)Jasem J, Altoos B, Fisher CM, Elias AD, Kounalakis N, Borges VF, Kabos P. Multiple Hepatic Lesions in a Patient With a History of DCIS. Oncology (Williston Park). 2015 Sep; 29(9):669-70, 678-9.Oncology (Williston Park)2015-09-01T00:00:002015Multiple Hepatic Lesions in a Patient With a History of DCIS.Authorship 1358561126687066Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MUJ, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, Ford HLNature communicationsTowers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MUJ, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, Ford HL. The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. Nat Commun. 2015 Dec 21; 6:10077.Nat Commun2015-12-21T00:00:002015The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p.Authorship 141195527150721Gillen AE, Yamamoto TM, Kline E, Hesselberth JR, Kabos PBMC genomicsGillen AE, Yamamoto TM, Kline E, Hesselberth JR, Kabos P. Improvements to the HITS-CLIP protocol eliminate widespread mispriming artifacts. BMC Genomics. 2016 05 05; 17:338.BMC Genomics2016-05-05T00:00:002016Improvements to the HITS-CLIP protocol eliminate widespread mispriming artifacts.Authorship 1422417Authorship 142390727001563Jasem J, Amini A, Rabinovitch R, Borges VF, Elias A, Fisher CM, Kabos PJournal of clinical oncology : official journal of the American Society of Clinical OncologyJasem J, Amini A, Rabinovitch R, Borges VF, Elias A, Fisher CM, Kabos P. 21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile. J Clin Oncol. 2016 06 10; 34(17):1995-2002.J Clin Oncol2016-03-21T00:00:00201621-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.26411365Sartorius CA, Hanna CT, Gril B, Cruz H, Serkova NJ, Huber KM, Kabos P, Schedin TB, Borges VF, Steeg PS, Cittelly DMOncogeneSartorius CA, Hanna CT, Gril B, Cruz H, Serkova NJ, Huber KM, Kabos P, Schedin TB, Borges VF, Steeg PS, Cittelly DM. Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism. Oncogene. 2016 06 02; 35(22):2881-92.Oncogene2015-09-28T00:00:002015Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism.Authorship 1499351227702820Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, Kabos PClinical cancer research : an official journal of the American Association for Cancer ResearchBrechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, Kabos P. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. Clin Cancer Res. 2017 Apr 01; 23(7):1710-1721.Clin Cancer Res2016-10-04T00:00:002016Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen.Authorship 153039327854101Schade H, Davis L, Kabos POncology (Williston Park, N.Y.)Schade H, Davis L, Kabos P. Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer. Oncology (Williston Park). 2016 Nov 15; 30(11):992-4, 1000-1.Oncology (Williston Park)2016-11-15T00:00:002016Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer.Authorship 1545878Authorship 1546791527987198Overholser L, Shagisultanova E, Rabinovitch RA, Kounalakis N, Diamond J, Finlayson CA, Fisher CM, Kabos P, Elias AD, Borges VF, Mayordomo JOncology (Williston Park, N.Y.)Overholser L, Shagisultanova E, Rabinovitch RA, Kounalakis N, Diamond J, Finlayson CA, Fisher CM, Kabos P, Elias AD, Borges VF, Mayordomo J. Breast Cancer Following Radiation for Hodgkin Lymphoma: Clinical Scenarios and Risk-Reducing Strategies. Oncology (Williston Park). 2016 12 15; 30(12):1063-70.Oncology (Williston Park)2016-12-15T00:00:002016Breast Cancer Following Radiation for Hodgkin Lymphoma: Clinical Scenarios and Risk-Reducing Strategies.28025748Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MTCancer metastasis reviewsDobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev. 2016 12; 35(4):547-573.Cancer Metastasis Rev2016-12-01T00:00:002016Patient-derived xenograft (PDX) models in basic and translational breast cancer research.12865022Ehtesham M, Kabos P, Yong WH, Schievink WI, Black KL, Yu JSSurgical neurologyEhtesham M, Kabos P, Yong WH, Schievink WI, Black KL, Yu JS. Development of an intracranial ependymoma at the site of a pre-existing cavernous malformation. Surg Neurol. 2003 Jul; 60(1):80-2; discussion 83.Surg Neurol2003-07-01T00:00:002003Development of an intracranial ependymoma at the site of a pre-existing cavernous malformation.12499252Ehtesham M, Kabos P, Gutierrez MA, Chung NH, Griffith TS, Black KL, Yu JSCancer researchEhtesham M, Kabos P, Gutierrez MA, Chung NH, Griffith TS, Black KL, Yu JS. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 2002 Dec 15; 62(24):7170-4.Cancer Res2002-12-15T00:00:002002Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand.12504887Kabos P, Ehtesham M, Kabosova A, Black KL, Yu JSExperimental neurologyKabos P, Ehtesham M, Kabosova A, Black KL, Yu JS. Generation of neural progenitor cells from whole adult bone marrow. Exp Neurol. 2002 Dec; 178(2):288-93.Exp Neurol2002-12-01T00:00:002002Generation of neural progenitor cells from whole adult bone marrow.12616102Ehtesham M, Kabos P, Gutierrez MA, Samoto K, Black KL, Yu JSJournal of immunotherapy (Hagerstown, Md. : 1997)Ehtesham M, Kabos P, Gutierrez MA, Samoto K, Black KL, Yu JS. Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats. J Immunother. 2003 Mar-Apr; 26(2):107-16.J Immunother2003-03-01T00:00:002003Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats.KristinaMarkeyKristina Markey39.74389450000000-104.8394352000000012470Markey, KristinaInstructor12880376Kabos P, Ehtesham M, Black KL, Yu JSExpert opinion on biological therapyKabos P, Ehtesham M, Black KL, Yu JS. Neural stem cells as delivery vehicles. Expert Opin Biol Ther. 2003 Aug; 3(5):759-70.Expert Opin Biol Ther2003-08-01T00:00:002003Neural stem cells as delivery vehicles.15153341Ehtesham M, Yuan X, Kabos P, Chung NH, Liu G, Akasaki Y, Black KL, Yu JSNeoplasia (New York, N.Y.)Ehtesham M, Yuan X, Kabos P, Chung NH, Liu G, Akasaki Y, Black KL, Yu JS. Glioma tropic neural stem cells consist of astrocytic precursors and their migratory capacity is mediated by CXCR4. Neoplasia. 2004 May-Jun; 6(3):287-93.Neoplasia2004-05-01T00:00:002004Glioma tropic neural stem cells consist of astrocytic precursors and their migratory capacity is mediated by CXCR4.1Professor3Asst Professor2Assoc Professor4InstructorAuthorship 158610528090623Iyer P, Jasem J, Springer MA, Klein CE, Kabos POncology (Williston Park, N.Y.)Iyer P, Jasem J, Springer MA, Klein CE, Kabos P. PALB2-Positive Breast Cancer in a 40-Year-Old Man. Oncology (Williston Park). 2017 01 15; 31(1):50-2, 54.Oncology (Williston Park)2017-01-15T00:00:002017PALB2-Positive Breast Cancer in a 40-Year-Old Man.15147965Kabos P, Matundan H, Zandian M, Bertolotto C, Robinson ML, Davy BE, Yu JS, Krueger RCBiochemical and biophysical research communicationsKabos P, Matundan H, Zandian M, Bertolotto C, Robinson ML, Davy BE, Yu JS, Krueger RC. Neural precursors express multiple chondroitin sulfate proteoglycans, including the lectican family. Biochem Biophys Res Commun. 2004 Jun 11; 318(4):955-63.Biochem Biophys Res Commun2004-06-11T00:00:002004Neural precursors express multiple chondroitin sulfate proteoglycans, including the lectican family.Authorship 161950828404760Jasem J, Fisher CM, Amini A, Shagisultanova E, Rabinovitch R, Borges VF, Elias A, Kabos PJournal of the National Comprehensive Cancer Network : JNCCNJasem J, Fisher CM, Amini A, Shagisultanova E, Rabinovitch R, Borges VF, Elias A, Kabos P. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided? J Natl Compr Canc Netw. 2017 04; 15(4):494-503.J Natl Compr Canc Netw2017-04-01T00:00:002017The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?2018-01-31NIHKABOS, PETER2012-08-01Regulation of anti-endocrine resistance of breast cancer by a network of non-codiK08CA1640482021-03-31NIHKABOS, PETER2016-04-01Cancer-associated fibroblasts in estrogen receptor positive breast cancer.R01CA205044Principal InvestigatorPrincipal Investigator16615963Krueger RC, Wu H, Zandian M, Danielpour M, Kabos P, Yu JS, Sun YEThe Journal of pediatricsKrueger RC, Wu H, Zandian M, Danielpour M, Kabos P, Yu JS, Sun YE. Neural progenitors populate the cerebrospinal fluid of preterm patients with hydrocephalus. J Pediatr. 2006 Mar; 148(3):337-340.J Pediatr2006-03-01T00:00:002006Neural progenitors populate the cerebrospinal fluid of preterm patients with hydrocephalus.Authorship 163883828555173Ionkina AA, Tentler JJ, Kim J, Capasso A, Pitts TM, Ryall KA, Howison RR, Kabos P, Sartorius CA, Tan AC, Eckhardt SG, Diamond JRFrontiers in oncologyIonkina AA, Tentler JJ, Kim J, Capasso A, Pitts TM, Ryall KA, Howison RR, Kabos P, Sartorius CA, Tan AC, Eckhardt SG, Diamond JR. Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer. Front Oncol. 2017; 7:94.Front Oncol2017-05-15T00:00:002017Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer.18391223Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CAProceedings of the National Academy of Sciences of the United States of AmericaHorwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A. 2008 Apr 15; 105(15):5774-9.Proc Natl Acad Sci U S A2008-04-07T00:00:002008Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.19777765Diamond JR, Finlayson CA, Thienelt C, Kabos P, Hardesty L, Barbour L, Klein CE, Rabinovitch R, Elias A, Borges VFOncology (Williston Park, N.Y.)Diamond JR, Finlayson CA, Thienelt C, Kabos P, Hardesty L, Barbour L, Klein CE, Rabinovitch R, Elias A, Borges VF. Early-stage BRCA2-linked breast cancer diagnosed in the first trimester of pregnancy associated with a hypercoagulable state. Oncology (Williston Park). 2009 Aug; 23(9):784-91.Oncology (Williston Park)2009-08-01T00:00:002009Early-stage BRCA2-linked breast cancer diagnosed in the first trimester of pregnancy associated with a hypercoagulable state.Authorship 1671716Authorship 167533828729413Finlay-Schultz J, Gillen AE, Brechbuhl HM, Ivie JJ, Matthews SB, Jacobsen BM, Bentley DL, Kabos P, Sartorius CACancer researchFinlay-Schultz J, Gillen AE, Brechbuhl HM, Ivie JJ, Matthews SB, Jacobsen BM, Bentley DL, Kabos P, Sartorius CA. Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III. Cancer Res. 2017 09 15; 77(18):4934-4946.Cancer Res2017-07-20T00:00:002017Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III.28797765Stokes WA, Amini A, Jackson MW, Plimpton SR, Kounalakis N, Kabos P, Rabinovitch RA, Rusthoven CG, Fisher CMClinical breast cancerStokes WA, Amini A, Jackson MW, Plimpton SR, Kounalakis N, Kabos P, Rabinovitch RA, Rusthoven CG, Fisher CM. Patterns of Fractionation and Boost Usage in Adjuvant External Beam Radiotherapy for Ductal Carcinoma in Situ in the United States. Clin Breast Cancer. 2018 06; 18(3):220-228.Clin Breast Cancer2017-06-29T00:00:002017Patterns of Fractionation and Boost Usage in Adjuvant External Beam Radiotherapy for Ductal Carcinoma in Situ in the United States.Authorship 1678891328741260Wellberg EA, Checkley LA, Giles ED, Johnson SJ, Oljira R, Wahdan-Alaswad R, Foright RM, Dooley G, Edgerton SM, Jindal S, Johnson GC, Richer JK, Kabos P, Thor AD, Schedin P, MacLean PS, Anderson SMHormones & cancerWellberg EA, Checkley LA, Giles ED, Johnson SJ, Oljira R, Wahdan-Alaswad R, Foright RM, Dooley G, Edgerton SM, Jindal S, Johnson GC, Richer JK, Kabos P, Thor AD, Schedin P, MacLean PS, Anderson SM. The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer. Horm Cancer. 2017 12; 8(5-6):269-285.Horm Cancer2017-07-24T00:00:002017The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer.20665103Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A, Horwitz KB, Sartorius CABreast cancer research and treatmentKabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A, Horwitz KB, Sartorius CA. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat. 2011 Jul; 128(1):45-55.Breast Cancer Res Treat2010-07-28T00:00:002010Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers.Authorship 169549728912168Gillen AE, Brechbuhl HM, Yamamoto TM, Kline E, Pillai MM, Hesselberth JR, Kabos PMolecular cancer research : MCRGillen AE, Brechbuhl HM, Yamamoto TM, Kline E, Pillai MM, Hesselberth JR, Kabos P. Alternative Polyadenylation of PRELID1 Regulates Mitochondrial ROS Signaling and Cancer Outcomes. Mol Cancer Res. 2017 12; 15(12):1741-1751.Mol Cancer Res2017-09-14T00:00:002017Alternative Polyadenylation of PRELID1 Regulates Mitochondrial ROS Signaling and Cancer Outcomes.Authorship 171359829066505Banerji U, Dean EJ, P?rez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHMClinical cancer research : an official journal of the American Association for Cancer ResearchBanerji U, Dean EJ, P?rez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers. Clin Cancer Res. 2018 05 01; 24(9):2050-2059.Clin Cancer Res2017-10-24T00:00:002017A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.12801 E 17th Ave2RC1SResearch South Tower12801 E 17th AveAurora80045-2570CO11809764Kabos P, Kabosova A, Neuman TThe Journal of biological chemistryKabos P, Kabosova A, Neuman T. Blocking HES1 expression initiates GABAergic differentiation and induces the expression of p21(CIP1/WAF1) in human neural stem cells. J Biol Chem. 2002 Mar 15; 277(11):8763-6.J Biol Chem2002-01-24T00:00:002002Blocking HES1 expression initiates GABAergic differentiation and induces the expression of p21(CIP1/WAF1) in human neural stem cells.12499834Kabos P, Kabosova A, Neuman TNeuroreportKabos P, Kabosova A, Neuman T. Neuronal injury affects expression of helix-loop-helix transcription factors. Neuroreport. 2002 Dec 20; 13(18):2385-8.Neuroreport2002-12-20T00:00:002002Neuronal injury affects expression of helix-loop-helix transcription factors.16407848Ehtesham M, Winston JA, Kabos P, Thompson RCOncogeneEhtesham M, Winston JA, Kabos P, Thompson RC. CXCR4 expression mediates glioma cell invasiveness. Oncogene. 2006 May 04; 25(19):2801-6.Oncogene2006-05-04T00:00:002006CXCR4 expression mediates glioma cell invasiveness.19810890Ehtesham M, Kabos P, Black KL, Yu JSExpert review of neurotherapeuticsEhtesham M, Kabos P, Black KL, Yu JS. Use of neural stem cells as therapeutic vehicles for the treatment of malignant glioma. Expert Rev Neurother. 2003 Nov; 3(6):883-95.Expert Rev Neurother2003-11-01T00:00:002003Use of neural stem cells as therapeutic vehicles for the treatment of malignant glioma.20151846Kabos P, Borges VFExpert opinion on pharmacotherapyKabos P, Borges VF. Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer. Expert Opin Pharmacother. 2010 Apr; 11(5):807-16.Expert Opin Pharmacother2010-04-01T00:00:002010Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer.22751729Yoo BH, Axlund SD, Kabos P, Reid BG, Schaack J, Sartorius CA, LaBarbera DVJournal of biomolecular screeningYoo BH, Axlund SD, Kabos P, Reid BG, Schaack J, Sartorius CA, LaBarbera DV. A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer. J Biomol Screen. 2012 Oct; 17(9):1211-20.J Biomol Screen2012-06-29T00:00:002012A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer.22821401Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CABreast cancer research and treatmentKabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat. 2012 Sep; 135(2):415-32.Breast Cancer Res Treat2012-07-24T00:00:002012Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.23184698Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, Labarbera DV, Sartorius CAHormones & cancerAxlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, Labarbera DV, Sartorius CA. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties. Horm Cancer. 2013 Feb; 4(1):36-49.Horm Cancer2012-11-27T00:00:002012Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties.Authorship 1743361329164052Contreras-Z?rate MJ, Ormond DR, Gillen AE, Hanna C, Day NL, Serkova NJ, Jacobsen BM, Edgerton SM, Thor AD, Borges VF, Lillehei KO, Graner MW, Kabos P, Cittelly DMFrontiers in oncologyContreras-Z?rate MJ, Ormond DR, Gillen AE, Hanna C, Day NL, Serkova NJ, Jacobsen BM, Edgerton SM, Thor AD, Borges VF, Lillehei KO, Graner MW, Kabos P, Cittelly DM. Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases. Front Oncol. 2017; 7:252.Front Oncol2017-11-02T00:00:002017Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases.Authorship 183572229940061Stoen E, Kabos P, Borden KC, Brown RJ, Borges VF, Diamond JROncology (Williston Park, N.Y.)Stoen E, Kabos P, Borden KC, Brown RJ, Borges VF, Diamond JR. A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer. Oncology (Williston Park). 2018 06; 32(6):298-302.Oncology (Williston Park)2018-06-01T00:00:002018A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer.D001932Disorders23210160.547325Brain NeoplasmsD011980Chemicals & Drugs723260.831141Receptors, ProgesteroneAuthorship 184757230046001Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PSJCI insightWellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PS. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018 07 26; 3(14).JCI Insight2018-07-26T00:00:002018FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation.Authorship 185152930071865Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Sams S, Kabos P, Zolman K, Colvin T, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KDBreast cancer research : BCRDiamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Sams S, Kabos P, Zolman K, Colvin T, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. Breast Cancer Res. 2018 08 02; 20(1):82.Breast Cancer Res2018-08-02T00:00:002018A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.Authorship 191625930496484Riemondy KA, Ransom M, Alderman C, Gillen AE, Fu R, Finlay-Schultz J, Kirkpatrick GD, Di Paola J, Kabos P, Sartorius CA, Hesselberth JRNucleic acids researchRiemondy KA, Ransom M, Alderman C, Gillen AE, Fu R, Finlay-Schultz J, Kirkpatrick GD, Di Paola J, Kabos P, Sartorius CA, Hesselberth JR. Recovery and analysis of transcriptome subsets from pooled single-cell RNA-seq libraries. Nucleic Acids Res. 2019 02 28; 47(4):e20.Nucleic Acids Res2019-02-28T00:00:002019Recovery and analysis of transcriptome subsets from pooled single-cell RNA-seq libraries.D018719Chemicals & Drugs1073210.82094Receptor, ErbB-2Authorship 1986381530940654Stumpf PK, Cittelly DM, Robin TP, Carlson JA, Stuhr KA, Contreras-Zarate MJ, Lai S, Ormond DR, Rusthoven CG, Gaspar LE, Rabinovitch R, Kavanagh BD, Liu A, Diamond JR, Kabos P, Fisher CMClinical cancer research : an official journal of the American Association for Cancer ResearchStumpf PK, Cittelly DM, Robin TP, Carlson JA, Stuhr KA, Contreras-Zarate MJ, Lai S, Ormond DR, Rusthoven CG, Gaspar LE, Rabinovitch R, Kavanagh BD, Liu A, Diamond JR, Kabos P, Fisher CM. Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4. Clin Cancer Res. 2019 07 01; 25(13):3946-3953.Clin Cancer Res2019-04-02T00:00:002019Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4.D001943Disorders41719940.418243Breast NeoplasmsONC GENERAL OPERATIONSD011960Chemicals & Drugs1263880.793549Receptors, EstrogenSOM-MEDSOM-PathologyEndocrinologyBoneMarrow TransplantUniversity of Colorado Denver - Anschutz Medical CampusKathrynHorwitzKathryn Horwitz39.74389450000000-104.83943520000000122Horwitz, KathrynProfessor-ClinicalAnthonyEliasAnthony David Elias39.74009560000000-104.837619000000001506Elias, AnthonyProfessorThomasFlaigThomas William Flaig39.74389450000000-104.839435200000001920Flaig, ThomasProfessorJenniferDiamondJennifer R Diamond39.74389450000000-104.839435200000002074Diamond, JenniferAssociate ProfessorStephenKeysarStephen B Keysar39.74389450000000-104.839435200000003327Keysar, StephenAssoc Professor-ResearchCarolSartoriusCarol Ann Sartorius39.74389450000000-104.83943520000000591Sartorius, CarolProfessorAustinGillenAustin E. Gillen39.74389450000000-104.839435200000007355Gillen, AustinAsst Professor-ResearchPaulBunnPaul A Bunn39.74389450000000-104.8394352000000097Bunn, PaulProfessorVirginiaBorgesVirginia F. Borges39.74389450000000-104.839435200000001874Borges, VirginiaProfessor6.1530.00668874380research areas3.444470.022630870coauthor of108.76211.759460similar to1180selected publicationsAuthorship 119865Authorship 21593613Authorship 2159727Authorship 216248932045383Brechbuhl HM, Barrett AS, Kopin E, Hagen JC, Han AL, Gillen AE, Finlay-Schultz J, Cittelly DM, Owens P, Horwitz KB, Sartorius CA, Hansen K, Kabos PJCI insightBrechbuhl HM, Barrett AS, Kopin E, Hagen JC, Han AL, Gillen AE, Finlay-Schultz J, Cittelly DM, Owens P, Horwitz KB, Sartorius CA, Hansen K, Kabos P. Fibroblast subtypes define a metastatic matrisome in breast cancer. JCI Insight. 2020 02 27; 5(4).JCI Insight2020-02-27T00:00:002020Fibroblast subtypes define a metastatic matrisome in breast cancer.31969331Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders C, Carrillo J, Chalasani P, Kabos P, Puhalla S, Tkaczuk K, Garcia AA, Ahluwalia MS, Wefel JS, Lakhani N, Ibrahim NClinical cancer research : an official journal of the American Association for Cancer ResearchKumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders C, Carrillo J, Chalasani P, Kabos P, Puhalla S, Tkaczuk K, Garcia AA, Ahluwalia MS, Wefel JS, Lakhani N, Ibrahim N. ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clin Cancer Res. 2020 06 15; 26(12):2789-2799.Clin Cancer Res2020-01-22T00:00:002020ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases.31988452McGinn O, Ward AV, Fettig LM, Riley D, Ivie J, Paul KV, Kabos P, Finlay-Schultz J, Sartorius CAOncogeneMcGinn O, Ward AV, Fettig LM, Riley D, Ivie J, Paul KV, Kabos P, Finlay-Schultz J, Sartorius CA. Cytokeratin 5 alters ?-catenin dynamics in breast cancer cells. Oncogene. 2020 03; 39(12):2478-2492.Oncogene2020-01-27T00:00:002020Cytokeratin 5 alters ?-catenin dynamics in breast cancer cells.Authorship 222404832576280Finlay-Schultz J, Jacobsen BM, Riley D, Paul KV, Turner S, Ferreira-Gonzalez A, Harrell JC, Kabos P, Sartorius CABreast cancer research : BCRFinlay-Schultz J, Jacobsen BM, Riley D, Paul KV, Turner S, Ferreira-Gonzalez A, Harrell JC, Kabos P, Sartorius CA. New generation breast cancer cell lines developed from patient-derived xenografts. Breast Cancer Res. 2020 06 23; 22(1):68.Breast Cancer Res2020-06-23T00:00:002020New generation breast cancer cell lines developed from patient-derived xenografts.Authorship 224483532694159Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Di?ras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CKClinical cancer research : an official journal of the American Association for Cancer ResearchTolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Di?ras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2020 10 15; 26(20):5310-5319.Clin Cancer Res2020-07-21T00:00:002020A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.Authorship 225476932822091Brechbuhl HM, Vinod-Paul K, Gillen AE, Kopin EG, Gibney K, Elias AD, Hayashi M, Sartorius CA, Kabos PMolecular carcinogenesisBrechbuhl HM, Vinod-Paul K, Gillen AE, Kopin EG, Gibney K, Elias AD, Hayashi M, Sartorius CA, Kabos P. Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells. Mol Carcinog. 2020 10; 59(10):1129-1139.Mol Carcinog2020-08-21T00:00:002020Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells.Authorship 228755833063469Weiss JA, Nicklawsky A, Kagihara JA, Gao D, Fisher C, Elias A, Borges VF, Kabos P, Davis SL, Leong S, Eckhardt SG, Diamond JRCancer medicineWeiss JA, Nicklawsky A, Kagihara JA, Gao D, Fisher C, Elias A, Borges VF, Kabos P, Davis SL, Leong S, Eckhardt SG, Diamond JR. Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center. Cancer Med. 2020 12; 9(23):8801-8808.Cancer Med2020-10-16T00:00:002020Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center.Authorship 2305415Authorship 2313351933144693Dwyer AR, Truong TH, Kerkvliet CP, Paul KV, Kabos P, Sartorius CA, Lange CABritish journal of cancerDwyer AR, Truong TH, Kerkvliet CP, Paul KV, Kabos P, Sartorius CA, Lange CA. Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor+ breast cancer. Br J Cancer. 2021 01; 124(1):217-227.Br J Cancer2020-11-04T00:00:002020Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor+ breast cancer.33257795Maller O, Drain AP, Barrett AS, Borgquist S, Ruffell B, Zakharevich I, Pham TT, Gruosso T, Kuasne H, Lakins JN, Acerbi I, Barnes JM, Nemkov T, Chauhan A, Gruenberg J, Nasir A, Bjarnadottir O, Werb Z, Kabos P, Chen YY, Hwang ES, Park M, Coussens LM, Nelson AC, Hansen KC, Weaver VMNature materialsMaller O, Drain AP, Barrett AS, Borgquist S, Ruffell B, Zakharevich I, Pham TT, Gruosso T, Kuasne H, Lakins JN, Acerbi I, Barnes JM, Nemkov T, Chauhan A, Gruenberg J, Nasir A, Bjarnadottir O, Werb Z, Kabos P, Chen YY, Hwang ES, Park M, Coussens LM, Nelson AC, Hansen KC, Weaver VM. Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. Nat Mater. 2021 04; 20(4):548-559.Nat Mater2020-11-30T00:00:002020Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression.Authorship 2338858Authorship 23503514Authorship 2360066Authorship 236365533406490Sakamoto MR, Eguchi M, Azelby CM, Diamond JR, Fisher CM, Borges VF, Bradley CJ, Kabos PJournal of the National Comprehensive Cancer Network : JNCCNSakamoto MR, Eguchi M, Azelby CM, Diamond JR, Fisher CM, Borges VF, Bradley CJ, Kabos P. New Persistent Opioid and Benzodiazepine Use After Curative-Intent Treatment in Patients With Breast Cancer. J Natl Compr Canc Netw. 2021 01 06; 19(1):29-38.J Natl Compr Canc Netw2021-01-06T00:00:002021New Persistent Opioid and Benzodiazepine Use After Curative-Intent Treatment in Patients With Breast Cancer.33513026Bardia A, Kaklamani V, Wilks S, Weise A, Richards D, Harb W, Osborne C, Wesolowski R, Karuturi M, Conkling P, Bagley RG, Wang Y, Conlan MG, Kabos PJournal of clinical oncology : official journal of the American Society of Clinical OncologyBardia A, Kaklamani V, Wilks S, Weise A, Richards D, Harb W, Osborne C, Wesolowski R, Karuturi M, Conkling P, Bagley RG, Wang Y, Conlan MG, Kabos P. Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. J Clin Oncol. 2021 04 20; 39(12):1360-1370.J Clin Oncol2021-01-29T00:00:002021Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.33625615Stoen E, Kagihara J, Shagisultanova E, Fisher CM, Nicklawsky A, Kabos P, Borges VF, Diamond JRBreast cancer research and treatmentStoen E, Kagihara J, Shagisultanova E, Fisher CM, Nicklawsky A, Kabos P, Borges VF, Diamond JR. Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval. Breast Cancer Res Treat. 2021 Jun; 187(3):883-891.Breast Cancer Res Treat2021-02-24T00:00:002021Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval.33649192Tolaney SM, Sahebjam S, Rhun EL, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Di?ras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CKClinical cancer research : an official journal of the American Association for Cancer ResearchTolaney SM, Sahebjam S, Rhun EL, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Di?ras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK. Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast Cancer. Clin Cancer Res. 2021 Mar 01; 27(5):1582.Clin Cancer Res2021-03-01T00:00:002021Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast Cancer.Authorship 2387984Authorship 238414733816286Schreiber AR, Kagihara JA, Weiss JA, Nicklawsky A, Gao D, Borges VF, Kabos P, Diamond JRFrontiers in oncologySchreiber AR, Kagihara JA, Weiss JA, Nicklawsky A, Gao D, Borges VF, Kabos P, Diamond JR. Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials. Front Oncol. 2021; 11:640690.Front Oncol2021-03-17T00:00:002021Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials.33863913Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Jhaveri K, Varga A, Wong A, Schram AM, Ambrose H, Carr TH, de Bruin EC, Salinas-Souza C, Foxley A, Hauser J, Lindemann JPO, Maudsley R, McEwen R, Moschetta M, Nikolaou M, Schiavon G, Razavi P, Banerji U, Baselga J, Hyman DM, Chandarlapaty SNPJ breast cancerSmyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Jhaveri K, Varga A, Wong A, Schram AM, Ambrose H, Carr TH, de Bruin EC, Salinas-Souza C, Foxley A, Hauser J, Lindemann JPO, Maudsley R, McEwen R, Moschetta M, Nikolaou M, Schiavon G, Razavi P, Banerji U, Baselga J, Hyman DM, Chandarlapaty S. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. NPJ Breast Cancer. 2021 Apr 16; 7(1):44.NPJ Breast Cancer2021-04-16T00:00:002021Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.Authorship 24978811Authorship 251175434705147Schreiber AR, Kagihara J, Eguchi M, Kabos P, Fisher CM, Meyer E, Molina E, Kondapalli L, Bradley CJ, Diamond JRBreast cancer research and treatmentSchreiber AR, Kagihara J, Eguchi M, Kabos P, Fisher CM, Meyer E, Molina E, Kondapalli L, Bradley CJ, Diamond JR. Evaluating anthracycline?+?taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study. Breast Cancer Res Treat. 2022 Jan; 191(2):389-399.Breast Cancer Res Treat2021-10-27T00:00:002021Evaluating anthracycline?+?taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study.34544797M?rquez-Ortiz RA, Contreras-Z?rate MJ, Tesic V, Alvarez-Eraso KLF, Kwak G, Littrell Z, Costello JC, Sreekanth V, Ormond DR, Karam SD, Kabos P, Cittelly DMClinical cancer research : an official journal of the American Association for Cancer ResearchM?rquez-Ortiz RA, Contreras-Z?rate MJ, Tesic V, Alvarez-Eraso KLF, Kwak G, Littrell Z, Costello JC, Sreekanth V, Ormond DR, Karam SD, Kabos P, Cittelly DM. IL13Ra2 Promotes Proliferation and Outgrowth of Breast Cancer Brain Metastases. Clin Cancer Res. 2021 11 15; 27(22):6209-6221.Clin Cancer Res2021-09-20T00:00:002021IL13Ra2 Promotes Proliferation and Outgrowth of Breast Cancer Brain Metastases.Authorship 252824734728571Shagisultanova E, Crump LS, Borakove M, Hall JK, Rasti AR, Harrison BA, Kabos P, Lyons TR, Borges VFMolecular cancer therapeuticsShagisultanova E, Crump LS, Borakove M, Hall JK, Rasti AR, Harrison BA, Kabos P, Lyons TR, Borges VF. Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2. Mol Cancer Ther. 2022 01; 21(1):48-57.Mol Cancer Ther2021-11-02T00:00:002021Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2.Authorship 2533031334856027Brechbuhl HM, Xie M, Kopin EG, Han AL, Vinod-Paul K, Hagen J, Edgerton S, Owens P, Sams S, Elias A, Sartorius CA, Tan AC, Kabos PMolecular carcinogenesisBrechbuhl HM, Xie M, Kopin EG, Han AL, Vinod-Paul K, Hagen J, Edgerton S, Owens P, Sams S, Elias A, Sartorius CA, Tan AC, Kabos P. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer. Mol Carcinog. 2022 03; 61(3):359-371.Mol Carcinog2021-12-02T00:00:002021Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer.Authorship 259909835406548Ward AV, Matthews SB, Fettig LM, Riley D, Finlay-Schultz J, Paul KV, Jackman M, Kabos P, MacLean PS, Sartorius CACancersWard AV, Matthews SB, Fettig LM, Riley D, Finlay-Schultz J, Paul KV, Jackman M, Kabos P, MacLean PS, Sartorius CA. Estrogens and Progestins Cooperatively Shift Breast Cancer Cell Metabolism. Cancers (Basel). 2022 Mar 31; 14(7).Cancers (Basel)2022-03-31T00:00:002022Estrogens and Progestins Cooperatively Shift Breast Cancer Cell Metabolism.Authorship 263091535639459McGinn O, Riley D, Finlay-Schultz J, Paul KV, Kabos P, Sartorius CAMolecular cancer research : MCRMcGinn O, Riley D, Finlay-Schultz J, Paul KV, Kabos P, Sartorius CA. Cytokeratins 5 and 17 Maintain an Aggressive Epithelial State in Basal-Like Breast Cancer. Mol Cancer Res. 2022 09 02; 20(9):1443-1455.Mol Cancer Res2022-09-02T00:00:002022Cytokeratins 5 and 17 Maintain an Aggressive Epithelial State in Basal-Like Breast Cancer.Authorship 2755486Authorship 274461236001652Rao S, Han AL, Zukowski A, Kopin E, Sartorius CA, Kabos P, Ramachandran SScience advancesRao S, Han AL, Zukowski A, Kopin E, Sartorius CA, Kabos P, Ramachandran S. Transcription factor-nucleosome dynamics from plasma cfDNA identifies ER-driven states in breast cancer. Sci Adv. 2022 08 26; 8(34):eabm4358.Sci Adv2022-08-24T00:00:002022Transcription factor-nucleosome dynamics from plasma cfDNA identifies ER-driven states in breast cancer.36335120Rugo HS, Kabos P, Beck JT, Jerusalem G, Wildiers H, Sevillano E, Paz-Ares L, Chisamore MJ, Chapman SC, Hossain AM, Chen Y, Tolaney SMNPJ breast cancerRugo HS, Kabos P, Beck JT, Jerusalem G, Wildiers H, Sevillano E, Paz-Ares L, Chisamore MJ, Chapman SC, Hossain AM, Chen Y, Tolaney SM. Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study. NPJ Breast Cancer. 2022 Nov 05; 8(1):118.NPJ Breast Cancer2022-11-05T00:00:002022Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study.Authorship 277398836824740Contreras-Z?rate MJ, Alvarez-Eraso KL, Jaramillo-G?mez JA, Littrell Z, Tsuji N, Ormond DR, Karam SD, Kabos P, Cittelly DMbioRxiv : the preprint server for biologyContreras-Z?rate MJ, Alvarez-Eraso KL, Jaramillo-G?mez JA, Littrell Z, Tsuji N, Ormond DR, Karam SD, Kabos P, Cittelly DM. Short-term Topiramate treatment prevents radiation-induced cytotoxic edema in preclinical models of breast-cancer brain metastasis. bioRxiv. 2023 Feb 15.bioRxiv2023-02-15T00:00:002023Short-term Topiramate treatment prevents radiation-induced cytotoxic edema in preclinical models of breast-cancer brain metastasis.Authorship 256521Authorship 280618536965330Roy S, Lakritz S, Schreiber AR, Molina E, Kabos P, Wood M, Elias A, Kondapalli L, Bradley CJ, Diamond JREuropean journal of cancer (Oxford, England : 1990)Roy S, Lakritz S, Schreiber AR, Molina E, Kabos P, Wood M, Elias A, Kondapalli L, Bradley CJ, Diamond JR. Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study. Eur J Cancer. 2023 05; 185:69-82.Eur J Cancer2023-02-28T00:00:002023Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study.37053041Contreras-Z?rate MJ, Alvarez-Eraso KLF, Jaramillo-G?mez JA, Littrell Z, Tsuji N, Ormond DR, Karam SD, Kabos P, Cittelly DMNeuro-oncologyContreras-Z?rate MJ, Alvarez-Eraso KLF, Jaramillo-G?mez JA, Littrell Z, Tsuji N, Ormond DR, Karam SD, Kabos P, Cittelly DM. Short-term topiramate treatment prevents radiation-induced cytotoxic edema in preclinical models of breast-cancer brain metastasis. Neuro Oncol. 2023 10 03; 25(10):1802-1814.Neuro Oncol2023-10-03T00:00:002023Short-term topiramate treatment prevents radiation-induced cytotoxic edema in preclinical models of breast-cancer brain metastasis.Authorship 2828723Authorship 283102837131107Travers SS, Fisher CM, Kabos P, Cittelly DM, Ormond DRJournal of neuro-oncologyTravers SS, Fisher CM, Kabos P, Cittelly DM, Ormond DR. Breast cancer brain metastases localization and risk of hydrocephalus: a single institution experience. J Neurooncol. 2023 May; 163(1):115-121.J Neurooncol2023-05-02T00:00:002023Breast cancer brain metastases localization and risk of hydrocephalus: a single institution experience.37210417Elias AD, Spoelstra NS, Staley AW, Sams S, Crump LS, Vidal GA, Borges VF, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, D'Alessandro A, Zolman KL, van Bokhoven A, Zhuang Y, Gallagher RI, Wulfkuhle JD, Petricoin Iii EF, Gao D, Richer JKNPJ breast cancerElias AD, Spoelstra NS, Staley AW, Sams S, Crump LS, Vidal GA, Borges VF, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, D'Alessandro A, Zolman KL, van Bokhoven A, Zhuang Y, Gallagher RI, Wulfkuhle JD, Petricoin Iii EF, Gao D, Richer JK. Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer. NPJ Breast Cancer. 2023 May 20; 9(1):41.NPJ Breast Cancer2023-05-20T00:00:002023Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer.Authorship 2842261237363965Shagisultanova E, Gradishar W, Brown-Glaberman U, Chalasani P, Brenner AJ, Stopeck A, Parris H, Gao D, McSpadden T, Mayordomo J, Diamond JR, Kabos P, Borges VFClinical cancer research : an official journal of the American Association for Cancer ResearchShagisultanova E, Gradishar W, Brown-Glaberman U, Chalasani P, Brenner AJ, Stopeck A, Parris H, Gao D, McSpadden T, Mayordomo J, Diamond JR, Kabos P, Borges VF. Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer. Clin Cancer Res. 2023 Dec 15; 29(24):5021-5030.Clin Cancer Res2023-12-15T00:00:002023Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer.HeatherBrechbuhlHeather M Brechbuhl39.74389450000000-104.839435200000008240Brechbuhl, HeatherAsst Professor-Researchtrue1Professor-ClinicalProfessor-Clinicaltrue1Asst Professor-ResearchAsst Professor-ResearchAuthorship 291357337742278Schreiber AR, O'Bryant CL, Kabos P, Diamond JRExpert review of anticancer therapySchreiber AR, O'Bryant CL, Kabos P, Diamond JR. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan. Expert Rev Anticancer Ther. 2023 Jul-Dec; 23(10):1061-1069.Expert Rev Anticancer Ther2023-10-26T00:00:002023The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.true1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Assoc Professor-ResearchAssoc Professor-Researchtrue1InstructorInstructortrue1ProfessorProfessortrue1Asst Professor-ResearchAsst Professor-ResearchAuthorship 2927188Authorship 296552Authorship 2941281037921755Jhaveri KL, Bellet M, Turner NC, Loi S, Bardia A, Boni V, Sohn J, Neilan TG, Villanueva-V?zquez R, Kabos P, Garc?a-Est?vez L, L?pez-Miranda E, P?rez-Fidalgo JA, P?rez-Garc?a JM, Yu J, Fredrickson J, Moore HM, Chang CW, Bond JW, Eng-Wong J, Gates MR, Lim EClinical cancer research : an official journal of the American Association for Cancer ResearchJhaveri KL, Bellet M, Turner NC, Loi S, Bardia A, Boni V, Sohn J, Neilan TG, Villanueva-V?zquez R, Kabos P, Garc?a-Est?vez L, L?pez-Miranda E, P?rez-Fidalgo JA, P?rez-Garc?a JM, Yu J, Fredrickson J, Moore HM, Chang CW, Bond JW, Eng-Wong J, Gates MR, Lim E. Phase Ia/b Study of Giredestrant ? Palbociclib and ? Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer. Clin Cancer Res. 2024 Feb 16; 30(4):754-766.Clin Cancer Res2024-02-16T00:00:002024Phase Ia/b Study of Giredestrant ? Palbociclib and ? Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer.true1ProfessorProfessortrue1ProfessorProfessor2026-06-30NIHSARTORIUS, CAROL ANN2022-08-01Hormone Receptor Regulation of RNA Polymerase IIIR01GM146373Co-Principal InvestigatorAuthorship 316905Authorship 327451true1ProfessorProfessorAuthorship 442471Authorship 1087266Authorship 109007624038734Balakrishnan I, Yang X, Brown J, Ramakrishnan A, Torok-Storb B, Kabos P, Hesselberth JR, Pillai MMStem cells (Dayton, Ohio)Balakrishnan I, Yang X, Brown J, Ramakrishnan A, Torok-Storb B, Kabos P, Hesselberth JR, Pillai MM. Genome-wide analysis of miRNA-mRNA interactions in marrow stromal cells. Stem Cells. 2014 Mar; 32(3):662-73.Stem Cells2014-03-01T00:00:002014Genome-wide analysis of miRNA-mRNA interactions in marrow stromal cells.24596682Reid BG, Jerjian T, Patel P, Zhou Q, Yoo BH, Kabos P, Sartorius CA, Labarbera DVCurrent chemical genomics and translational medicineReid BG, Jerjian T, Patel P, Zhou Q, Yoo BH, Kabos P, Sartorius CA, Labarbera DV. Live multicellular tumor spheroid models for high-content imaging and screening in cancer drug discovery. Curr Chem Genom Transl Med. 2014; 8(Suppl 1):27-35.Curr Chem Genom Transl Med2014-02-07T00:00:002014Live multicellular tumor spheroid models for high-content imaging and screening in cancer drug discovery.Authorship 45823Authorship 474591Authorship 487751Authorship 492251Authorship 111545824906430Pillai MM, Gillen AE, Yamamoto TM, Kline E, Brown J, Flory K, Hesselberth JR, Kabos PBreast cancer research and treatmentPillai MM, Gillen AE, Yamamoto TM, Kline E, Brown J, Flory K, Hesselberth JR, Kabos P. HITS-CLIP reveals key regulators of nuclear receptor signaling in breast cancer. Breast Cancer Res Treat. 2014 Jul; 146(1):85-97.Breast Cancer Res Treat2014-06-07T00:00:002014HITS-CLIP reveals key regulators of nuclear receptor signaling in breast cancer.Authorship 112657722765220Iwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP, Ford HLBreast cancer research : BCRIwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP, Ford HL. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res. 2012 Jul 05; 14(4):R100.Breast Cancer Res2012-07-05T00:00:002012Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.Authorship 601463Authorship 612823Authorship 619972Authorship 638002Authorship 115334824497407Carlson JA, Nooruddin Z, Rusthoven C, Elias A, Borges VF, Diamond JR, Kavanagh B, Kabos PNeuro-oncologyCarlson JA, Nooruddin Z, Rusthoven C, Elias A, Borges VF, Diamond JR, Kavanagh B, Kabos P. Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. Neuro Oncol. 2014 Jul; 16(7):1006-9.Neuro Oncol2014-07-01T00:00:002014Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema.